General Updates | Targeting CALR with immunotherapy in MPNs
Johannes Foßelteder
• 17 May 2022
Johannes Foßelteder, Medical University of Graz, Graz, Austria, comments on the potential of targeting calreticulin (CALR)-mutated myeloproliferative neoplasm (MPN) progenitors with a neoepitope-directed monoclonal antibody and with T-cells engineered to target CALR. Recent evidence from experiments in in vitro and in vivo models has shown that monoclonal antibodies and T-cells engineered to target CALR induce efficient killing of mutant cells. This interview took place virtually.
